Mundipharma acquires rights to sell Zevalin

18 November 2015

UK based pharma company Mundipharma International has acquired the rights to sell and distribute Zevalin (ibritumomab tiuxetan) from US biotech firm Spectrum Pharmaceuticals (Nasdaq: SPPI), it has been announced.

Under the new licence and asset purchase agreement, Mundipharma will have rights related to marketing and sales and access to existing inventory of Zevalin from Spectrum across Asia Pacific.

Spectrum will receive an up-front payment of $15 million plus $5 million in profits on initial Zevalin supply. Spectrum will continue to own Zevalin rights for the USA, Canada, and Europe.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK